Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal

Clinical Genitourinary Cancer

Volumn 5, Issue 6, 2007, Pages 401-402

  Kundranda, Madappa N ^a,b   Muslimani, Alaa ^b   Daw, Hamed A ^a   Spiro, Timothy P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b FAIRVIEW HOSPITAL   (United States)

Author keywords

Antiandrogen therapy; Leuprolide; Prostate specific antigen

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DRUG ACTIVITY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NEEDLE BIOPSY; PROSTATE CARCINOMA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 35348862417     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2007.n.024     Document Type: Article

References (6)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366-381.
2. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15:2928-2938.
3. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 2000; 23:381-390.
4. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B study 9663. J Clin Oncol 2003; 21:2673-2678.
5. Small EJ, Halabi S, Kantoff P, et al. Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee. Clin Cancer Res 2006; 12:3596s-3600s.
6. El-Gabry EA, Strup SE, Gomella LG. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon. Tech Urol 2000; 6:221-222.